drugset

drugset / Trial / NCT06487078

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

NCT06487078 ↗

Recruiting 90 enrolled Pfizer

NaSingle-groupOpen-labelTreatment

Summary

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World context

Timeline

Start: 2025-01-20
Primary completion: 2028-11-30
Completion: 2028-11-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lorlatinib	Small molecule	100 mg	Oral

Indications